127 related articles for article (PubMed ID: 8666124)
21. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
22. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.
Cortellaro M; Nencioni T; Boschetti C; Ortolani S; Buzzi F; Francucci B; Caraceni MP; Abelli P; Polvani F; Zanussi C
Eur J Clin Pharmacol; 1991; 41(6):555-9. PubMed ID: 1667755
[TBL] [Abstract][Full Text] [Related]
23. [Hormone substitution treatment of the menopause].
González-Merlo J; Castelo-Branco C; Celades M
Rev Med Univ Navarra; 1992; 37(3):143-51. PubMed ID: 1336213
[No Abstract] [Full Text] [Related]
24. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
Utian WH; Speroff L; Ellman H; Dart C
Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group.
Gordon SF; Thompson KA; Ruoff GE; Imig JR; Lane PJ; Schwenker CE
Int J Fertil Menopausal Stud; 1995; 40(3):126-34. PubMed ID: 7663539
[TBL] [Abstract][Full Text] [Related]
26. [Estrogen metabolism and hormone substitution in the climacteric].
Göretzlehner G; Kyank H
Zentralbl Gynakol; 1985; 107(16):977-88. PubMed ID: 2996259
[TBL] [Abstract][Full Text] [Related]
27. Effect of transdermal estradiol and oral conjugated equine estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
Wakatsuki A; Okatani Y; Fukaya T
Circulation; 2003 May; 107(18):e127-8; author reply e127-8. PubMed ID: 12742976
[No Abstract] [Full Text] [Related]
28. [Effects of oral administration of estrogen replacement therapy in surgical menopause].
Bomba-Opoń DA; Niesłuchowska-Frydrych B; Szucka-May H; Kamiński P; Marianowski L
Ginekol Pol; 2001 Dec; 72(12A):1377-82. PubMed ID: 11883282
[TBL] [Abstract][Full Text] [Related]
29. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women.
Dupont A; Dupont P; Cusan L; Tremblay M; Rioux J; Cloutier D; Mailloux J; De Lignières B; Gutkowska J; Boucher H
Maturitas; 1991 Oct; 13(4):297-311. PubMed ID: 1663571
[TBL] [Abstract][Full Text] [Related]
30. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.
Perrone G; Stefanutti C; Galoppi P; Anelli G; Capri O; Lucani G; Vivenzio A; Mazzarella B; Zichella L
Int J Fertil Menopausal Stud; 1996; 41(6):509-15. PubMed ID: 9010744
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with a 7-day estrogen patch: principles and practice.
Notelovitz M
Gynecol Endocrinol; 1998 Aug; 12(4):248-58. PubMed ID: 9798134
[TBL] [Abstract][Full Text] [Related]
32. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
34. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
Winkler UH; Krämer R; Kwee B; Schindler AE
Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
[TBL] [Abstract][Full Text] [Related]
35. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
36. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
[TBL] [Abstract][Full Text] [Related]
37. [Transdermal administration of estrogens in women with the postcastration and climacteric syndromes].
Rotta L; Matĕchová E
Cesk Gynekol; 1992 Sep; 57(7):336-40. PubMed ID: 1394497
[TBL] [Abstract][Full Text] [Related]
38. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.
Moorjani S; Dupont A; Labrie F; De Lignieres B; Cusan L; Dupont P; Mailloux J; Lupien PJ
J Clin Endocrinol Metab; 1991 Aug; 73(2):373-9. PubMed ID: 1649840
[TBL] [Abstract][Full Text] [Related]
39. [Transdermal and oral hormone substitution with estrogens: a comparison].
Schindler AE
Zentralbl Gynakol; 1995; 117(10):504-7. PubMed ID: 7491831
[TBL] [Abstract][Full Text] [Related]
40. Estrogen replacement therapy.
Alcoff JM
Am Fam Physician; 1982 Jun; 25(6):183-6. PubMed ID: 6282102
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
